Literature DB >> 25450598

Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma.

Pei Zhang1, Xiaoming Lu1, Kaixiong Tao1, Liang Shi2, Wei Li1, Guobin Wang1, Ke Wu3.   

Abstract

BACKGROUND: The interaction between Siglec-10 and its ligand, CD24, selectively represses tissue damage-caused immune responses. However, the nature of Siglec-10 and CD24 in human hepatocellular carcinoma (HCC) is still poorly defined. Hereon, the expression, function, and regulation of CD24 and Siglec-10 in HCC were investigated in the present study.
METHODS: Flow cytometry was performed to examine the expression of Siglec-10 in HCC tissues and adjacent non-tumor tissues of HCC patients. To further determine whether Siglec-10 expression is associated with the clinical characteristics and survival, conventional immunohistochemistry was performed in 96 HCC patients. Additionally, the role of Siglec-10 in the regulation of natural killer (NK) cell dysfunction was evaluated. Finally, CD24 expression in HCC was also assessed.
RESULTS: Siglec-10 was expressed most on NK cells in HCC (40.7 ± 4.5%). Compared with surrounding non-tumor tissues, tumor tissues had higher Siglec-10 expression (31.0 ± 1.7% versus 40.7 ± 4.5%, n = 10, P < 0.05), and the expression was negatively associated with patient survival. Siglec-10(+)CD56(+) NK cells exhibited reduced effector function, as shown by decreased granules and cytokine expressions compared with Siglec-10(-)CD56(+) NK cells. Moreover, the number of CD24(+)CD45(-) cells in HCC tissues was higher than that in adjacent non-tumor tissues (9.4 ± 0.9% versus 3.1 ± 0.9%, n = 15, P < 0.05).
CONCLUSIONS: These findings suggest that Siglec-10 is associated with decreased survival and impaired NK cell function in human HCC. This process may function via the CD24-Siglec-10 interaction, which may represent a therapeutic target in HCC patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD24; HCC; Siglec-10

Mesh:

Substances:

Year:  2014        PMID: 25450598     DOI: 10.1016/j.jss.2014.09.035

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  25 in total

1.  Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.

Authors:  L Tao; S Wang; L Yang; L Jiang; J Li; X Wang
Journal:  Clin Exp Immunol       Date:  2020-05-17       Impact factor: 4.330

2.  Decreased expression of Siglec-8 associates with poor prognosis in patients with gastric cancer after surgical resection.

Authors:  Yifan Cao; Hao Liu; Heng Zhang; Chao Lin; Ruochen Li; Weijuan Zhang; Zhenbin Shen; Jiejie Xu
Journal:  Tumour Biol       Date:  2016-02-16

Review 3.  The intriguing roles of Siglec family members in the tumor microenvironment.

Authors:  Kui-Ying Jiang; Li-Li Qi; Fu-Biao Kang; Ling Wang
Journal:  Biomark Res       Date:  2022-04-13

4.  Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.

Authors:  Philip Rosenstock; Rüdiger Horstkorte; Vinayaga Srinivasan Gnanapragassam; Jörg Harth; Heike Kielstein
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

5.  Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.

Authors:  Qiong-Fang Zhang; Wen-Wei Yin; Yang Xia; Ya-Yang Yi; Qiu-Feng He; Xing Wang; Hong Ren; Da-Zhi Zhang
Journal:  Cell Mol Immunol       Date:  2016-06-20       Impact factor: 11.530

6.  Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10.

Authors:  Rosa Ester Forgione; Cristina Di Carluccio; Juan Guzmán-Caldentey; Rosa Gaglione; Filomena Battista; Fabrizio Chiodo; Yoshiyuki Manabe; Angela Arciello; Pompea Del Vecchio; Koichi Fukase; Antonio Molinaro; Sonsoles Martín-Santamaría; Paul R Crocker; Roberta Marchetti; Alba Silipo
Journal:  iScience       Date:  2020-06-02

Review 7.  A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease.

Authors:  Olivier Lucar; R Keith Reeves; Stephanie Jost
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

8.  Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.

Authors:  Nan Xiao; Xiaodong Zhu; Kangshuai Li; Yifan Chen; Xuefeng Liu; Bin Xu; Ming Lei; Jiejie Xu; Hui-Chuan Sun
Journal:  Exp Hematol Oncol       Date:  2021-06-10

Review 9.  Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.

Authors:  Shan-Shan Yin; Feng-Hou Gao
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

10.  Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus.

Authors:  Xiaojing Ren; Yuanyuan Ji; Xuhua Jiang; Xun Qi
Journal:  Biosci Rep       Date:  2018-11-28       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.